[Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia].
The effectiveness of domestic alpha 2-interferon preparation reaferon was studied in vivo and in vitro for eradication of pathological hemopoietic clone in chronic myeloid leukemia. Reaferon administration for 1-30 months produced cytogenetic remission in 7%, hematological remission in 21%, partial hematological remission in 36% of the patients. Reaferon is indicated in chronic myeloid leukemia without splenomegaly. In the disease progression reaferon is uneffective. Mechanism of reaferon therapeutic action comprises three components: a direct antiproliferative effect on hemopoietic precursor cells, activation of cellular immunity, an effect on stem cell microenvironment.
Abdulkadyrov
K M
KM
Moiseev
S I
SI
Shcherbakova
E G
EG
Balashova
V A
VA
Glazanova
T V
TV
Rukavitsyn
O A
OA
Martynkevich
I S
IS
Gritsaev
S V
SV
Blinov
M N
MN
D000328:Adult; D015703:Antigens, CD / Q000097:blood; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001856:Bone Marrow Examination; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins; D012074:Remission Induction; D018709:Statistics, Nonparametric; D013997:Time Factors
D015703:Antigens, CD; D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D006918:Hydroxyurea
Opyt primeneniia reaferona (al'fa 2-interferona) dlia lecheniia bol'nykh khronicheskim mieloleĭkozom.